NASDAQ:NRIX 8 December 2025

Nurix Shares Jump Premarket on Roche $2.3 Billion Cancer Drug Deal

Nurix Therapeutics shares surged in premarket trading Monday after Roche said it will pay $700 million upfront for development and commercialization rights to bexobrutideg, Nurix’s experimental drug for blood cancers and immune diseases. The stock, listed on Nasdaq, traded at $17.62 at 8:00 a.m. ET, up 20.4% from Friday’s close.

8 June 2026

NASDAQ:NRIX·Pharmaceuticals·Stock Market

Cathie Wood Sells $40M in Tesla, Keeps Cutting Iridium, and Adds Nurix: What ARK Invest’s Latest Trades Signal on Dec. 15, 2025

Cathie Wood’s ARK Invest is heading into mid-December with a familiar playbook: rotate aggressively, publish the receipts, and keep investors guessing about what “disruptive innovation” looks like in a market that’s re-pricing risk.

15 December 2025

NASDAQ:HOOD·NASDAQ:IRDM·NASDAQ:NRIX·NASDAQ:SQ·NASDAQ:TSLA·Stock Market·Tesla

Biggest Stock Losers Today in the U.S. (Dec. 10, 2025): DYN, SLM, KTB, WAY and More Slide as Fed Decision Looms

U.S. stocks are trading in a holding pattern on Wednesday, December 10, 2025, as Wall Street waits for the Federal Reserve’s final interest‑rate decision of the year. Index moves are modest, but beneath the surface a cluster of mid‑cap names is posting double‑digit percentage declines, led by Dyne Therapeutics, SLM Corp, Kontoor Brands and Waystar Holding. Investing.com+1

10 December 2025

Federal Reserve·NASDAQ:DYN·NASDAQ:LEGN·NASDAQ:MBX·NASDAQ:NRIX·NASDAQ:SLM·NASDAQ:SMMT·NASDAQ:WAY·NYSE:AAP·NYSE:GPK·NYSE:KTB·Stock Market

Nurix Therapeutics (NRIX) Stock Soars on ASH 2025 Trial Data: Latest News, Analyst Forecasts and Outlook as of December 8, 2025

Nurix Therapeutics, Inc. is back in the spotlight. On December 8, 2025, the biotech stock surged roughly 20% intraday after the company released new Phase 1 data for its Bruton’s tyrosine kinase degrader bexobrutideg in blood cancers at the American Society of Hematology Annual Meeting and scheduled a corporate webcast for this evening. MarketBeat+3GlobeNewswire+3GlobeNewswire+3

8 December 2025